Skip to content

19-412 - A Study of Brentuximab Vedotin in Adults Age 60 and Above With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Status: open

A phase 2 open-label study of brentuximab vedotin in front-line therapy of Hodgkin lymphoma (HL) and CD30-expressing peripheral T-cell lymphoma (PTCL) in adults age 60 and above

Treatment for Hodgkin Lymphoma

Contact Us


The trial will study brentuximab vedotin to find out whether it is an effective treatment in patients 60 years or older for Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL). The study will look at brentuximab vedotin alone and combined with other drugs.


This trial is sponsored by Seattle Genetics.

Providers Associated With This Trial

Principle Investigator

  • Omar AlkharabshehView Profile
    Omar Alkharabsheh, M.D.Medical Oncologist and HematologistAssociate Professor of Interdisciplinary Clinical Oncology; Associate Program Director, Medical Oncology Fellowship

Sub Investigators

    This link will open in a new tab or window.